A citation-based method for searching scientific literature

Ottavio Giampietro, Chiara Giampietro, Luca Della Bartola, Maria Chiara Masoni, Elena Matteucci. Drug Des Devel Ther 2013
Times Cited: 22







List of co-cited articles
167 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.
S L Ellis, E G Moser, J K Snell-Bergeon, A S Rodionova, R M Hazenfield, S K Garg. Diabet Med 2011
88
54

Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
Satish K Garg, Emily G Moser, Bruce W Bode, Leslie J Klaff, William R Hiatt, Christie Beatson, Janet K Snell-Bergeon. Endocr Pract 2013
66
45

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.
K V S Hari Kumar, Altamash Shaikh, Pitambar Prusty. Diabetes Res Clin Pract 2013
59
40



The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control.
Iben Brock Jacobsen, Jan Erik Henriksen, Henning Beck-Nielsen. Basic Clin Pharmacol Toxicol 2009
34
22

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Robert R Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C Griffen. Diabetes Care 2015
148
22

Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes.
Kristina I Rother, Lisa M Spain, Robert A Wesley, Benigno J Digon, Alain Baron, Kim Chen, Patric Nelson, H-Michael Dosch, Jerry P Palmer, Barbara Brooks-Worrell,[...]. Diabetes Care 2009
95
18

The use of metformin in type 1 diabetes: a systematic review of efficacy.
S Vella, L Buetow, P Royle, S Livingstone, H M Colhoun, J R Petrie. Diabetologia 2010
119
18

CD26, let it cut or cut it down.
I De Meester, S Korom, J Van Damme, S Scharpé. Immunol Today 1999
379
18

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.
J Andrew Pospisilik, Jennifer Martin, Timothy Doty, Jan A Ehses, Nathalie Pamir, Francis C Lynn, Shalea Piteau, Hans-Ulrich Demuth, Christopher H S McIntosh, Raymond A Pederson. Diabetes 2003
269
18

Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study.
Søren Søgaard Lund, Lise Tarnow, Anne Sofie Astrup, Peter Hovind, Peter Karl Jacobsen, Amra Ciric Alibegovic, Ida Parving, Lotte Pietraszek, Merete Frandsen, Peter Rossing,[...]. PLoS One 2008
54
18

Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes.
Johan Farngren, Margaretha Persson, Anja Schweizer, James E Foley, Bo Ahrén. J Clin Endocrinol Metab 2012
63
18

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Arthur T Sands, Brian P Zambrowicz, Julio Rosenstock, Pablo Lapuerta, Bruce W Bode, Satish K Garg, John B Buse, Phillip Banks, Rubina Heptulla, Marc Rendell,[...]. Diabetes Care 2015
120
18

Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.
Nitesh D Kuhadiya, Ritu Malik, Natalie J Bellini, Jane Lyons Patterson, Andrea Traina, Antoine Makdissi, Paresh Dandona. Endocr Pract 2013
55
18

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
T R Pieber, S Famulla, J Eilbracht, J Cescutti, N Soleymanlou, O E Johansen, H J Woerle, U C Broedl, S Kaspers. Diabetes Obes Metab 2015
99
18

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Anne L Peters, Elizabeth O Buschur, John B Buse, Pejman Cohan, Jamie C Diner, Irl B Hirsch. Diabetes Care 2015
407
18

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Thomas Fremming Dejgaard, Christian Seerup Frandsen, Tanja Stenbæk Hansen, Thomas Almdal, Søren Urhammer, Ulrik Pedersen-Bjergaard, Tonny Jensen, Andreas Kryger Jensen, Jens Juul Holst, Lise Tarnow,[...]. Lancet Diabetes Endocrinol 2016
67
18


Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study.
J E Schopman, J B L Hoekstra, B M Frier, M T Ackermans, J J J de Sonnaville, A M Stades, R Zwertbroek, B Hartmann, J J Holst, F K Knop,[...]. Diabetes Obes Metab 2015
13
30

Liraglutide as additional treatment for type 1 diabetes.
Ajay Varanasi, Natalie Bellini, Deepti Rawal, Mehul Vora, Antoine Makdissi, Sandeep Dhindsa, Ajay Chaudhuri, Paresh Dandona. Eur J Endocrinol 2011
97
13

Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets.
R Ratner, F Whitehouse, M S Fineman, S Strobel, L Shen, D G Maggs, O G Kolterman, C Weyer. Exp Clin Endocrinol Diabetes 2005
40
13

Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26).
Bertram Bengsch, Bianca Seigel, Tobias Flecken, Julia Wolanski, Hubert E Blum, Robert Thimme. J Immunol 2012
99
13

Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody.
D A Fox, R E Hussey, K A Fitzgerald, O Acuto, C Poole, L Palley, J F Daley, S F Schlossman, E L Reinherz. J Immunol 1984
294
13

The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves β-cell mass in non-obese diabetic mice.
Jacob Jelsing, Niels Vrang, Søren B van Witteloostuijn, Michael Mark, Thomas Klein. J Endocrinol 2012
35
13

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Gary A Herman, Arthur Bergman, Catherine Stevens, Paul Kotey, Bingming Yi, Peng Zhao, Bruno Dietrich, George Golor, Andreas Schrodter, Bart Keymeulen,[...]. J Clin Endocrinol Metab 2006
377
13


The structure and function of CD26 in the T-cell immune response.
C Morimoto, S F Schlossman. Immunol Rev 1998
326
13


Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.
Zubair Shah, Thomas Kampfrath, Jeffrey A Deiuliis, Jixin Zhong, Colleen Pineda, Zhekang Ying, Xiaohua Xu, Bo Lu, Susan Moffatt-Bruce, Rekha Durairaj,[...]. Circulation 2011
264
13

Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.
Lei Tian, Jie Gao, Jianqiang Hao, Yu Zhang, Huimin Yi, Timothy D O'Brien, Robert Sorenson, Jian Luo, Zhiguang Guo. Endocrinology 2010
84
13

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Arthur J Bergman, Catherine Stevens, YanYan Zhou, Bingming Yi, Martine Laethem, Marina De Smet, Karen Snyder, Deborah Hilliard, Wesley Tanaka, Wei Zeng,[...]. Clin Ther 2006
206
13

Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs.
Lindsay B Harrison, Pablo F Mora, Gregory O Clark, Ildiko Lingvay. J Investig Med 2013
35
13

Dipeptidyl peptidase 4 inhibitor sitagliptin maintains β-cell function in patients with recent-onset latent autoimmune diabetes in adults: one year prospective study.
Yunjuan Zhao, Lin Yang, Yufei Xiang, Lingjiao Liu, Gan Huang, Zhaofeng Long, Xia Li, R David Leslie, Xiangbing Wang, Zhiguang Zhou. J Clin Endocrinol Metab 2014
69
13

The role of adjunctive exenatide therapy in pediatric type 1 diabetes.
Vandana S Raman, Kimberly J Mason, Luisa M Rodriguez, Krishnavathana Hassan, Xiaoying Yu, Lisa Bomgaars, Rubina A Heptulla. Diabetes Care 2010
60
13

Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial.
Jill Hamilton, Elizabeth Cummings, Vera Zdravkovic, Diane Finegood, Denis Daneman. Diabetes Care 2003
106
13


The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients.
Laurent Meyer, Philip Bohme, Irene Delbachian, Philippe Lehert, Nathalie Cugnardey, Pierre Drouin, Bruno Guerci. Diabetes Care 2002
58
13


A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
Fred Whitehouse, Davida F Kruger, Mark Fineman, Larry Shen, James A Ruggles, David G Maggs, Christian Weyer, Orville G Kolterman. Diabetes Care 2002
181
13

A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.
Steve Edelman, Satish Garg, Juan Frias, David Maggs, Yan Wang, Bei Zhang, Susan Strobel, Karen Lutz, Orville Kolterman. Diabetes Care 2006
98
13

Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.
Kellee M Miller, Nicole C Foster, Roy W Beck, Richard M Bergenstal, Stephanie N DuBose, Linda A DiMeglio, David M Maahs, William V Tamborlane. Diabetes Care 2015
740
13


DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.
Jixin Zhong, Andrei Maiseyeu, Stephen N Davis, Sanjay Rajagopalan. Circ Res 2015
110
13

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.
A J Tremblay, B Lamarche, C F Deacon, S J Weisnagel, P Couture. Diabetes Obes Metab 2011
118
13

Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks.
Nitesh D Kuhadiya, Sandeep Dhindsa, Husam Ghanim, Aditya Mehta, Antoine Makdissi, Manav Batra, Sartaj Sandhu, Jeanne Hejna, Kelly Green, Natalie Bellini,[...]. Diabetes Care 2016
43
13

Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial.
Ingrid M Libman, Kellee M Miller, Linda A DiMeglio, Kathleen E Bethin, Michelle L Katz, Avni Shah, Jill H Simmons, Michael J Haller, Sripriya Raman, William V Tamborlane,[...]. JAMA 2015
94
13


Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus.
Etsuko Nagai, Tomoyuki Katsuno, Jun-Ichiro Miyagawa, Kosuke Konishi, Masayuki Miuchi, Fumihiro Ochi, Yoshiki Kusunoki, Masaru Tokuda, Kazuki Murai, Tomoya Hamaguchi,[...]. Endocr J 2011
18
11

Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy.
Kathrin Herrmann, Juan P Frias, Steven V Edelman, Karen Lutz, Kevin Shan, Steven Chen, David Maggs, Orville G Kolterman. Postgrad Med 2013
12
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.